Pranjali Dalvi | Senior Scientist
Amgen

Pranjali Dalvi, Senior Scientist, Amgen

I am currently a Senior Scientist at Amgen in the Therapeutic Area group, primarily working on developing bispecific antibodies and T cell engagers for immuno-oncology. Before Amgen, I was at Teneobio since July 2019 as Scientist III (and later Senior Scientist) in the Pre-Clinical Assays group, where my main role was to lead TNB-585 (PSMAxCD3 bispecific) and TNB-738 (anti-CD38) programs. I came to Teneobio from Apexigen, where I primarily worked on the development of clinical assays for Sotigalimab and designed immunization plans and pre-clinical assays for their myeloid and Treg targets in pipeline. I got 5 years of postdoctoral training at the University of Kansas Medical Center, Division of Pulmonary and Critical Care Medicine in Dr. Navneet Dhillon’s lab, where I dileneated the molecular mechanism of HIV related pulmonary hypertension in drug abusers. I earned my Ph.D. in Microbiology from the University of Mumbai in a self-driven collaboration with Rossari Biotech.

Appearances:



Festival of Biologics Day 1 @ 17:10

Building multi-specific antibodies for immuno-oncology

  • Sequence based discovery engine for antibody screening.
  • Discovery and development of AMG-340, a PSMAxCD3 bispecific antibody against metastatic castration resistant prostate cancer.
  • Engineering UniAbs to safely target FOLR1 while sparing normal target-expressing cells.
last published: 01/Jul/22 16:05 GMT

back to speakers